Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of “Hold” from Brokerages

Sage Therapeutics, Inc. (NASDAQ:SAGE) has earned a consensus rating of “Hold” from the twenty ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $11.53.

Several equities analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $26.00 price target (down previously from $52.00) on shares of Sage Therapeutics in a research report on Wednesday, October 30th. Robert W. Baird reduced their target price on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. StockNews.com lowered shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Raymond James reissued a “market perform” rating on shares of Sage Therapeutics in a report on Thursday, October 10th. Finally, HC Wainwright restated a “neutral” rating and issued a $14.00 target price on shares of Sage Therapeutics in a research note on Wednesday, November 20th.

Sage Therapeutics Stock Down 1.4 %

Shares of NASDAQ SAGE opened at $5.27 on Wednesday. The company has a market capitalization of $322.38 million, a PE ratio of -0.94 and a beta of 0.87. The stock’s 50 day moving average price is $6.17 and its 200-day moving average price is $8.30. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $10.80 million. During the same period in the prior year, the firm posted ($2.81) EPS. The firm’s revenue for the quarter was up 337.1% on a year-over-year basis. As a group, research analysts expect that Sage Therapeutics will post -6.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SAGE. RTW Investments LP raised its position in shares of Sage Therapeutics by 2.0% in the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after buying an additional 111,123 shares in the last quarter. Federated Hermes Inc. purchased a new stake in shares of Sage Therapeutics in the 2nd quarter valued at about $7,281,000. Charles Schwab Investment Management Inc. boosted its position in shares of Sage Therapeutics by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after acquiring an additional 43,617 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Sage Therapeutics by 1,476.6% during the second quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock worth $6,010,000 after purchasing an additional 518,296 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Sage Therapeutics during the second quarter worth about $1,008,000. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.